Cargando…
Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial
Amfepramone (AFP) is an appetite-suppressant drug used in the treatment of obesity. Nonetheless, studies on interindividual pharmacokinetic variability and its association with genetic variants are limited. We employed a pharmacokinetic and pharmacogenetic approach to determine possible metabolic ph...
Autores principales: | Gómez-Silva, Magdalena, Piñeyro-Garza, Everardo, Vargas-Zapata, Rigoberto, Gamino-Peña, María Elena, León-García, Armando, de León, Mario Bermúdez, Llerena, Adrián, León-Cachón, Rafael B. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882847/ https://www.ncbi.nlm.nih.gov/pubmed/31780765 http://dx.doi.org/10.1038/s41598-019-54436-z |
Ejemplares similares
-
A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers
por: León-Cachón, Rafael B. R., et al.
Publicado: (2016) -
Mechanisms involved in the vasorelaxant effects produced by the acute
application of amfepramone in vitro to rat aortic
rings
por: López-Canales, J.S., et al.
Publicado: (2015) -
Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
por: Roco, Ángela, et al.
Publicado: (2014) -
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients
por: Lucchetta, Rosa Camila, et al.
Publicado: (2017) -
ERRATUM: Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients
Publicado: (2018)